AAAnusha Abdullah

Anusha Abdullah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anusha Abdullah has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Ina Dewenter

    Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany

    2 shared publications
  • Katharina Theresa Obermeier

    Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany

    2 shared publications
  • Sven Otto

    Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Lindwurmstrasse 2a, 80337 Munich, Germany

    2 shared publications
  • Wenko Smolka

    Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany

    2 shared publications
  • David Steybe

    Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Munich, Germany

    1 shared publication
  • Eric Hesse

    Institute of Musculoskeletal Medicine, Musculoskeletal University Center Munich, University Hospital, LMU Munich, Munich, Germany

    1 shared publication

Latest Publications

  • Open Access

    X-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?

    by Anusha Abdullah, Sabina Noreen Wuersching, Maximilian Kollmuss, Philipp Poxleitner, Ina Dewenter, Leonard Simon Brandenburg, David Steybe, Florian Nepomuk Fegg, Wenko Smolka, Sven Otto, et al.

    X-linked hypophosphatemia is a rare, hereditary disorder that significant influences teeth and alveolar bone. The first clinical sign leading to the diagnosis of X-linked hypophosphatemia is often dental impairment with dental abscesses and dentin mineralization defects. Genetic analysis helped find the responsible gene and therefore opened up new ways of therapeutically managing X-linked hypophosphatemia. The human monoclonal antibody Burosumab represents a milestone in the targeted therapy of this hereditary disease by directly addressing its pathophysiology. Targeted therapy has been shown to improve skeletal impairment, pain, and phosphate metabolism. However, the influence of this new therapy on dental impairment has only been addressed in a few recent studies with varying results. Therefore, in this review, we aim to summarize the dental phenotype and analyze the different treatment modalities with a focus on dental impairment.


  • Open Access

    Fibrous Dysplasia of the Jaw: Advances in Imaging and Treatment

    by Katharina Theresa Obermeier, Jens Tobias Hartung, Tim Hildebrandt, Ina Dewenter, Wenko Smolka, Eric Hesse, Florian Fegg, Sven Otto, Yoana Malenova, Anusha Abdullah

    A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesions, misdiagnosis often occurs and can lead to inadequate treatment. Particularly in the jaw, this lesion does not become quiescent during puberty, making fundamental knowledge about the diagnosis and treatment of FD crucial. Mutational analysis and nonsurgical approaches offer new diagnostic and therapeutic options. In this review, we examine the advances and the difficulties of the diagnosis and the various treatment modalities of FD of the jaw in order to capture the current scientific knowledge on this bone disease.